Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-000983
Filing Date
2025-03-27
Accepted
2025-03-27 17:28:34
Documents
81
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1809739
2 ex4-14.htm EX-4.14 16871
3 ex10-11.htm EX-10.11 67216
4 ex19-1.htm EX-19.1 58583
5 ex23-1.htm EX-23.1 3903
6 ex31-1.htm EX-31.1 18142
7 ex31-2.htm EX-31.2 16804
8 ex32-1.htm EX-32.1 10447
  Complete submission text file 0001641172-25-000983.txt   8597619

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE awh-20241231.xsd EX-101.SCH 63544
10 XBRL CALCULATION FILE awh-20241231_cal.xml EX-101.CAL 63052
11 XBRL DEFINITION FILE awh-20241231_def.xml EX-101.DEF 282917
12 XBRL LABEL FILE awh-20241231_lab.xml EX-101.LAB 569170
13 XBRL PRESENTATION FILE awh-20241231_pre.xml EX-101.PRE 426549
84 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1076088
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-34810 | Film No.: 25780653
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)